Shares of Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) saw unusually-strong trading volume on Thursday . Approximately 2,279,592 shares traded hands during mid-day trading, an increase of 200% from the previous session’s volume of 759,358 shares.The stock last traded at $1.96 and had previously closed at $1.68.

The company has a debt-to-equity ratio of 4.64, a quick ratio of 0.92 and a current ratio of 1.00. The stock has a market capitalization of $112.37, a price-to-earnings ratio of -1.17 and a beta of 1.30.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.37) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.02. Aralez Pharmaceuticals had a negative net margin of 112.89% and a negative return on equity of 118.13%. The firm had revenue of $24.30 million during the quarter, compared to the consensus estimate of $22.87 million. During the same quarter last year, the firm earned ($0.32) EPS. The firm’s revenue for the quarter was up 78.7% compared to the same quarter last year. equities research analysts predict that Aralez Pharmaceuticals Inc will post -1.54 EPS for the current year.

In other news, Director Arthur S. Kirsch acquired 50,000 shares of the firm’s stock in a transaction on Friday, December 8th. The stock was acquired at an average price of $1.47 per share, with a total value of $73,500.00. Following the completion of the purchase, the director now directly owns 271,609 shares in the company, valued at $399,265.23. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.70% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Wells Fargo & Company MN lifted its stake in Aralez Pharmaceuticals by 71.3% in the third quarter. Wells Fargo & Company MN now owns 273,130 shares of the company’s stock worth $625,000 after purchasing an additional 113,720 shares during the last quarter. Ballentine Partners LLC lifted its stake in Aralez Pharmaceuticals by 166.7% in the third quarter. Ballentine Partners LLC now owns 80,000 shares of the company’s stock worth $183,000 after purchasing an additional 50,000 shares during the last quarter. Brown Advisory Securities LLC bought a new stake in Aralez Pharmaceuticals in the third quarter worth about $394,000. Intrinsic Edge Capital Management LLC bought a new stake in Aralez Pharmaceuticals in the second quarter worth about $270,000. Finally, GSA Capital Partners LLP lifted its stake in Aralez Pharmaceuticals by 88.5% in the second quarter. GSA Capital Partners LLP now owns 541,795 shares of the company’s stock worth $731,000 after purchasing an additional 254,400 shares during the last quarter. 19.41% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This report was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2018/01/18/aralez-pharmaceuticals-arlz-sees-large-volume-increase.html.

About Aralez Pharmaceuticals

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.